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Abstract 
 
Aims. There is evidence that accumulation of α-synuclein (α-syn) in Parkinson’s disease (PD) 
and dementia with Lewy bodies (DLB) results from impaired removal of α-syn rather than its 
overproduction.  Kallikrein-6 (KLK6), calpain-1 (CAPN1) and cathepsin-D (CTSD) are among a 
small number of proteases that cleave α-syn and are dysregulated in PD and DLB. Our aim in 
this study was to determine whether protease activity is altered in another α-
synucleinopathy, multiple system atrophy (MSA), and might thereby modulate the regional 
distribution of α-syn accumulation. 
Methods. mRNA and protein level and/or activity of KLK6, CAPN1 and CTSD were measured 
and assessed in relation to α-syn load in multiple brain regions (posterior frontal cortex, 
caudate nucleus, putamen, occipital cortex, pontine base and cerebellar white matter), in 
MSA (n = 20) and age-matched post-mortem control tissue (n = 20).  
Results. CTSD activity was elevated in MSA in the pontine base and cerebellar white matter. 
KLK6 and CAPN1 levels were elevated in MSA in the putamen and cerebellar white matter. 
However, the activity or level of these proteolytic enzymes did not correlate with the 
regional distribution of α-syn.  
Conclusions. Accumulation of α-syn in MSA is not due to reduced activity of the proteases 
we have studied. We suggest that their upregulation is likely to be a compensatory response 
to increased α-syn in MSA.  
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Abbreviations 
AD  -  Alzheimer’s disease 
ALP  -  autophagy-lysosomal pathway 
α-syn  -  α-synuclein 
CAPN1  -  Calpain-1 
CSF  -  cerebrospinal fluid 
CTSD  -  Cathepsin D 
DLB  -  dementia with Lewy bodies 
GCIs  -  glial cytoplasmic inclusion  
KLK6  -  kallikrein-6 
MSA  -  multiple system atrophy 
NAC  -  non-amyloid-β component 
NCI  -  neuronal cytoplasmic inclusion 
NNI  -  neuronal nuclear inclusion 
PD  -  Parkinson’s disease 
SNCA  -  α-synuclein gene 
UPS  -  ubiquitin-proteasomal pathway 
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Introduction 
Abnormal aggregates of α-synuclein (α-syn) within neurons, neurites or glial cells are the 
defining neuropathological hallmark of the α-synucleinopathies. In Parkinson’s disease (PD) 
and dementia with Lewy bodies (DLB), the aggregates form characteristic neuronal and 
neuritic inclusions (Lewy bodies and neurites), while multiple system atrophy (MSA) is 
characterised by α-syn-containing glial cytoplasmic inclusions (GCIs) in oligodendrocytes. 
Smaller numbers of neuronal nuclear or cytoplasmic inclusions (NNI or NCI) are also a 
feature of the disease. In α-synucleinopathies, α-syn accumulates without increased SNCA 
mRNA expression (1-3), suggesting that impaired protein clearance may play a role in the 
pathogenesis of these disorders. The ubiquitin-proteasomal pathway (UPS) and the 
autophagy-lysosomal pathway (ALP) are major routes of α-syn clearance and have been 
shown to be dysregulated in PD and DLB (reviewed in (4-6)). Cathepsin D (CTSD) is the main 
lysosomal protease responsible for α-syn cleavage (7-9). CTSD-mediated α-syn cleavage 
reduces aggregation and toxicity of α-syn both in vitro and in vivo (7, 8), and is upregulated, 
probably as a compensatory response to elevated α-syn, in DLB and PD (10). 
A small number of non-lysosomal proteases including kallikrein-6 (KLK-6) (neurosin, 
zyme, protease M) (11-13) and calpain-1 (CAPN1) (14) have been shown to cleave and 
regulate α-syn level, both in vitro and in vivo. KLK6 and CAPN1 proteases cleave monomeric 
α-syn within the non-amyloid-β component (NAC) region, required for α-syn aggregation 
(15, 16), and generate cleavage fragments that are less neurotoxic and inhibit α-syn 
aggregation in vitro (8, 11, 12). KLK6 is expressed in neurons and oligodendrocytes (17-19); 
it is found within Lewy bodies and GCIs (18, 20) and degrades extracellular α-syn (13). Brain-
targeted, viral vector-mediated upregulation of KLK6 protects against α-syn pathology in 
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animal models of DLB (21) and MSA (22). CAPN1 is expressed neuronally and co-localises 
with α-syn in the cytosol (23). CAPN1 is capable of degrading both monomeric and fibrillar 
α-syn (14). Degradation of fibrillar α-syn by CAPN is, however, associated with accelerated 
α-syn aggregation, suggesting a complex relationship between CAPN1 activity and α-syn 
pathogenicity. We, and others, demonstrated that the expression and activity of KLK6 and 
CAPN1 are reduced in DLB and PD in human tissue and CSF (21, 23, 24) and in animal 
models (21), and that the extent of reduction correlates closely with α-syn accumulation 
(23).   
In this study we have explored the hypothesis that a reduction in proteolytic 
cleavage of α-syn is responsible for the elevated α-syn level in MSA. We have measured 
KLK6, CAPN1 and CTSD in MSA and assessed their association with α-syn load in brain 
regions with varied predilection for MSA pathology. Unlike in DLB, our findings do not 
support the hypothesis that the accumulation of α-syn in MSA is associated with reduced 
proteolytic clearance. The upregulation of the three proteases in regions with high α-syn 
load is probably a physiological (if ineffective) response to the increase in α-syn.   
 
Materials and Methods 
Case selection  
20 MSA and 20 control brains were used for biochemical assessment of enzyme 
protein/activity and measurement of α-syn load (See Table 1). A subset of 6 control and 6 
mixed MSA cases were used for western immunoblotting and NanoString nCounter mRNA 
expression studies. Mixed MSA cases were selected, based on Ozawa criteria (25). MSA can 
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be subdivided according to the distribution of pathology into three subcategories: 
striatonigral degeneration (SND), olivopontocerebellar atrophy (OPCA), and a combination 
of the two known as mixed MSA. For the current study we chose to use mixed MSA cases 
(hereafter referred to simply as MSA cases) to allow us to compare the findings in multiple 
brain regions within a single dataset.  
Human brain tissue 
All brains had been donated to the Queen Square Brain Bank for Neurological Disorders, 
UCL Institute of Neurology. The brain donation programme and protocols have ethical 
approval from the NRES Committee London–Central, and tissue is stored for research under 
a licence issued by the Human Tissue Authority (No. 12198).  
 The right hemisphere was sliced, and the slices flash frozen and stored at -80°C. 
Tissue was dissected from the frontal lobe, caudate nucleus, putamen, pontine base, 
occipital lobe and cerebellar white matter and homogenised in lysis buffer: 50mM Tris, 175 
mM NaCl, protease and phosphatase inhibitor tablet and 1% Triton-X (all reagents from 
Roche/Merck, UK), in a Precellys 24 homogeniser with ceramic beads (Bertin technologies, 
France). The left half-brain was fixed in 10% buffered formalin, sliced, tissue blocks selected 
for paraffin wax embedding, and 8 μm sections prepared for histology. 
 
NanoString nCounter analysis 
We used NanoString nCounter Human Inflammation panel v2 mRNA Expression Assay 
(NanoString Technologies, Seattle, WA) to quantify transcripts of the three α-syn-degrading 
enzymes. Total mRNA was isolated from frontal lobe and cerebellar white matter of 6 
Page 6 of 31Neuropathology and Applied Neurobiology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
control and 6 MSA cases (Table 1). 150 ng of total RNA from each sample was analysed. 
Probes were designed according to the manufacturer’s design principles (26), including 
screening for inter- and intra-reporter and capture probe interactions, and selection for 
probes with optimal melting temperature (26). The laboratory running the assay was 
blinded to the diagnosis. To avoid run-order bias, samples of cases or controls were 
randomly assigned to plates. Raw counts were subjected to a technical normalisation and 
normalized to the geometric mean using nSolver Analysis Software v2.0 (NanoString). For 
biological normalization we used reference genes (CLTC, GAPDH, GUSB, HPRT1, PGK1, TUBB) 
included in the CodeSet. The NanoString data were analysed using NanoString nSolver 
software. Data from NanoString nCounter expression counts were inspected and any 
samples determined to be outliers relative to negative controls were excluded from further 
analysis. The count data were normalised to negative controls and to positive controls 
according to the manufacturer’s instructions, correcting for differences in hybridization 
efficiency and processing variables including purification and RNA/reporter complex 
immobilisation. Two-tailed Student’s t tests were used to test for significant difference in 
gene expression between MSA and control frontal lobe and cerebellar white matter. The 
Benjamini-Yekutieli method was used to exclude false positive results. 
Immunohistochemistry 
Immunohistochemistry was performed with anti-α-syn (Catalogue number ab15530 at 
1:1300) (Abcam, UK) for 1 h and used a modified method for automated Intellipath FLX 
staining system (Menarini Diagnostics, Wokingham, UK) as per the manufacturer’s 
instructions.  Sections were pre-treated in the Menarini unit with an excess of super buffer 
and mounted in DPX with glass coverslips. Immunolabelled sections were processed by 
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digital slide scanner and images acquired using a Leica Aperio Imagescope. The percentage 
section area immunopositive for α-syn was determined by applying an Image J colour-
thresholding macro. 
Western immunoblotting 
Protein determination was performed by BCA assay (Pierce) as per the manufacturer’s 
instructions. For SDS-PAGE and western immunoblotting we used the XCell surelock blot 
system (Thermo Fisher Scientific). Samples diluted 20 μg/20 μl in MES buffer (Thermo Fisher 
Scientific) were run at 120 V. Proteins were transferred from the gel to nitrocellulose 
membrane (GE healthcare) in 1X transfer buffer (Thermo Fisher Scientific) at 37 V for 80 min 
on ice. The blots were analysed using the Odyssey system. The integrated area-density of 
immunoreactive bands at the predicted molecular weight for each protein of interest was 
quantified using Image J. Statistical analysis was performed using a two-tailed student t test 
in which significance was set at p < 0.05. 
Kallikrein-6 (KLK6) sandwich ELISA 
KLK6 level was determined in brain tissue homogenates by sandwich ELISA that was 
developed in-house, as previously described (23). Mouse monoclonal anti-KLK6 antibody 
(Sigma Aldrich, Dorset, UK) diluted in PBS (1:200) was used to coat wells in clear Costar
TM
 
high-binding 96-well microplates (R&D systems, Abingdown, UK) and was left overnight at 
room temperature (RT). The plates were washed in PBS 0.01% tween-20 five times and 
blocked for 3 h in 1%BSA/PBS at 26°C. Following a further wash step, tissue homogenates 
(6.5 μg total protein) and human recombinant standards (R&D systems, UK) diluted in PBS 
containing 1% BSA were added overnight at 4°C. After another wash, biotinylated goat 
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polyclonal anti-KLK6 antibody (1 μg/ml) (R&D systems, Cambridge, UK) diluted in 1 % 
BSA/PBS, was added for 2 h at 26°C. After further washes, streptavidin:HRP (1:200) (R&D 
systems, UK) diluted in PBS/0.01% tween-20 was added for 1 h at 26
o
C, the plate was 
washed, and chromogenic substrate (TMBS, R&D systems, UK) added for 20 min in the dark. 
The reaction was stopped with 2 N sulphuric acid, and absorbance read at 450 nM in a 
FLUOstar Optima plate reader. KLK6 concentration was determined by interpolation against 
measurements on serial dilutions of recombinant human KLK6 (720-11.25 ng/ml) included 
on each plate. All sample measurements were made in duplicate. 
Calpain-1 (CAPN1) fluorogenic activity assay 
CAPN1 activity was measured in brain tissue homogenates by use of an internally quenched 
fluorogenic substrate for CAPN1, as previously described (23). The substrate included the 
CAPN1-specific cleavage site in α-spectrin (1 μM, H-K(FAM)-EYY ~ GMMK(DABCYL)-OH 
(Millipore, Hertfordshire, UK)) and the assays wer  performed with or without the addition 
of a calpain-1-specific inhibitor (10 μM Tocris, Bristol, UK). Brain tissue homogenates and 
purified human CAPN1 (Sigma Aldrich, Dorset, UK) were diluted in assay buffer (10 μl of 
homogenate in 40 ul assay buffer, containing 50 mM Tris-HCL, 50 mN NaCL, 5 mM β-
mercaptoethanol, 5 mM CaCl2, 1 mM EGTA, 1 mM EDTA) pre-warmed to 37°C as described 
by Mittoo et al (27). Each sample and standard was added in duplicate to wells, with or 
without inhibitor, and left for 10 min at 37°C, prior to addition of the fluorogenic substrate 
which was also diluted in assay buffer. The reaction was left to proceed at 37°C for 3 h in the 
dark after which fluorescence was read in a FLUOstar Optima plate reader with excitation at 
490 nm and emission at 518 nm. For each sample the fluorescent signal in the inhibited 
wells was subtracted from that in the uninhibited wells. Measurements were repeated on 
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two separate occasions. The calpain-1 activity of each sample was interpolated from a 
standard curve derived from measurements on serial dilutions of calpain-1 (20-1.25 μg/ml); 
these were included in each plate to control for variation across plates. 
Cathepsin D (CTSD) fluorogenic activity assay 
CTSD enzyme activity was measured in brain tissue homogenates by adding a fluorogenic 
peptide substrate, Mca-Gly-Lys-Pro-Ile-Leu-Phe-Phe-Arg-Leu-Lys(Dnp)-D-Arg-NH2 [Mca= (7-
methoxycoumarin-4-yl)acetyl; Dnp=dinitrophenyl] (BML-P-145-001) at 20 μM (Enzo Life 
Sciences, Exeter, UK ) in the presence or absence of a specific cathepsin-D inhibitor 
(Pepstatin-A at 4μM).  Brain tissue homogenates (1.25 μl in 1 ml assay buffer) or purified 
cathepsin-D from liver (BML-SE199, Enzo Life Sciences, Exeter, UK) was diluted in assay 
buffer made up of 0.1 M sodium acetate and 0.1 M sodium chloride at pH 3.5. Each sample 
or standard was added in duplicate and incubated with or without pepstatin-A for 10 min at 
37°C prior to addition of the fluorogenic substrate. All components were diluted in assay 
buffer. The reaction was left to proceed at 37°C for 3 h in the dark after which fluorescence 
was read using a FLUOstar Optima plate reader with excitation at 320-340 nm and emission 
at 393-420 nm. For each sample the fluorescent signal in the inhibited wells was subtracted 
from that in the uninhibited wells. Each sample was measured in duplicate and 
measurements were repeated on two separate occasions. CTSD activity was interpolated 
from measurements on serial dilutions of serially recombinant CTSD that were included on 
each plate.   
Statistical analysis 
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Parametric statistical tests were used for comparisons between groups, and ANOVA with 
Bonferroni post-hoc test was used for multiple-group comparisons. In some cases the data 
required logarithmic transformation to obtain a normal distribution. For variables that were 
not normally distributed even after transformation, Kruskall-Wallis test was used, followed 
by Dunn’s test for pairwise intergroup comparisons. Pearson analysis was used to assess the 
correlation between pairs of variables. Statistical tests were performed using SPSS version 
16. P-values < 0.05 were considered statistically significant. 
Results 
KLK6, CTSD and CAPN1 mRNA 
We examined KLK6, CAPN1 and CTSD mRNA level in frontal lobe and cerebellar white 
matter from MSA and control brains. KLK6 mRNA level was significantly elevated in frontal 
lobe in MSA (4.53-fold increase) (P < 0.01). KLK6 mRNA level in the cerebellar white matter 
did not differ between MSA and control brains. CTSD and CAPN1 mRNA were unchanged in 
MSA compared to controls in any of the regions studied (Fig. 1). As in previous studies ((2, 
3), α-syn (SNCA) mRNA expression was not altered in MSA. 
KLK6, CTSD and CAPN1 protein 
We assessed KLK6, CAPN1 and CTSD protein level in a subset of brains, by western blot, in 
MSA and controls. KLK6 protein level was significantly elevated in the putamen (P < 0.05) 
but was unchanged in all other regions examined (Fig. 2). CAPN1 level, measured by western 
blot, was significantly increased in MSA in the putamen (P < 0.05) (Fig. 3) and cerebellar 
white matter (P < 0.01) (Fig. 3). CTSD level was unchanged in MSA in all regions (Fig. 4). 
Regional distribution of a-syn load in MSA 
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We determined the α-syn load (percentage section area immunopositive for α-syn) as an 
indicator of regional variation in severity of GCI pathology in MSA. The level of α-syn was 
highest in the pontine base and putamen, intermediate in the cerebellar white matter, 
frontal cortex, and caudate nucleus, and lowest in the occipital cortex (Fig. 5). 
Regional variation in KLK6, CAPN1 and CTSD level or activity in MSA  
We measured KLK6 protein level by ELISA, and CAPN1 and CTSD enzyme activities, in all 
regions, in the complete MSA and control cohorts. KLK6 level was significantly elevated in 
MSA in the putamen (P < 0.05) and cerebellar white matter (P < 0.0001) (Fig. 6A). CAPN1 
enzyme activity was significantly elevated in the putamen (P < 0.0001) and cerebellar white 
matter (P < 0.001) (Fig. 6B). CTSD activity was significantly elevated in the pontine base and 
cerebellar white matter in MSA (Fig. 6C).  
Regional variation in KLK6, CAPN1 and CTSD in relation to α-syn load in MSA 
Lastly, we assessed whether regional differences in α-syn load were related to KLK6, CAPN1 
or CTSD level or activity. Across the six regions examined, α-syn load did not correlate 
significantly with KLK6 level, or with CAPN1 or CTSD level or activity. KLK6 was generally 
reduced, and CAPN1 and CTSD activity tended to be elevated, in regions with higher α-syn 
load but none of these trends reached statistical significance (Fig 7)  
 
Discussion 
We have examined the expression of three proteases, previously shown to regulate 
α-syn homeostasis, in MSA, in relation to the α-syn load in different regions of brain. KLK6, 
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CAPN1 and CTSD were increased in MSA within the putamen, pontine base and cerebellar 
white matter – regions of high GCI burden and α-syn load in MSA. However, differences in 
α-syn load between regions were not correlated with the level or activity of KLK6, CAPN1 or 
CTSD. The findings contrast with our previous observations in PD and DLB (23), and indicate 
that accumulation of α-syn in MSA is unlikely to result from reduced activity of the 
proteases we have tested. The upregulation of these α-syn degrading enzymes in regions of 
high GCI burden and α-syn load is likely to be a compensatory response to elevated α-syn. It 
should be noted, of course, that we have only tested a small number of potential α-syn 
proteases, and it remains possible that others may be downregulated in MSA. 
Abnormal accumulation of α-syn in neurons and glial cells is a characteristic hallmark 
of PD, DLB and MSA. There is no evidence that α-syn mRNA level is increased in α-
synucleinopathies (1-3) suggesting that failure of proteolysis or removal by other means 
may contribute to the pathogenesis of MSA. The endosomal-lysosomal and autophagic 
pathways are major routes of α-syn clearance and have been shown to be dysregulated in 
PD and DLB (4-6, 28) and MSA (29-32). A small number of proteases have been identified 
that cleave and degrade intracellular and extracellular pools of α-syn in vitro and are down-
regulated in PD and DLB (23). KLK6, CAPN1 and CTSD are expressed neuronally, and within 
oligodendrocytes and are likely to impact on α-syn load in PD, DLB and MSA. KLK6, CAPN1 
and CTSD all have major cleavage sites within the non-Aβ component (NAC) region which is 
required for α-syn aggregation, and cleavage was shown to inhibit aggregation of full-length 
monomeric α-syn (15, 16). Brain-specific induction of KLK6 is protective against α-syn in 
mouse models of DLB (21) and MSA (22), and there is evidence that CTSD has protective 
effects in vivo (8). We, and others, showed previously that KLK6 and CAPN1 are reduced in 
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human brain tissue in PD and DLB and that the reduction is most marked in regions of 
cerebral cortex that contain the highest levels of α-syn (23). It seemed therefore reasonable 
to hypothesise that a reduction in proteolytic cleavage might contribute to α-syn 
accumulation in MSA. 
In the present study, we have explored the hypothesis that α-syn accumulation in 
MSA results, at least in part, from defective proteolytic clearance. We have chosen to study 
CTSD, CAPN1 and KLK6 in MSA because these enzymes are expressed within neurons and 
oligodendrocytes (17-19), are found within Lewy body inclusions and GCIs (11), are partly 
co-localised with α-syn in SH-SY5Y cells, and were shown to regulate α-syn levels in vivo and 
in vitro (33-37). CTSD is the primary enzyme responsible for lysosomal α-syn degradation (9) 
whereas KLK6 interacts with and degrades α-syn both intracellularly (11) and extracellularly 
(13, 34). A reduction in proteolytic activity of KLK6 has been proposed to play a role in the 
pathogenesis of α-synucleinopathies, including MSA (21-24). 
However, the present findings do not support our hypothesis. Instead, KLK6, CAPN1 
and CTSD were increased in MSA in regions that have a high α-syn load and pronounced 
MSA pathology: KLK6 and CAPN1 were elevated in the putamen and cerebellar white 
matter, and CTSD in the pontine base and cerebellar white matter. We failed to detect an 
association between regional α-syn load and the level or activity of any of the proteases. 
The most marked up-regulation of KLK6, CAPN1 and CTSD in regions with the highest α-syn 
burden is in keeping with previous observations suggesting that α-syn accumulation can 
upregulate degradative proteases in PD and DLB (10). Whether this is a compensatory 
response that affords any protection against α-syn accumulation but eventually becomes 
overwhelmed or even contributes to disease pathology (see below) is unknown.  
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Assessing the potential role of these enzymes in the pathogenesis of α-
synucleinopathies is complicated. Although cleavage of α-syn might be expected to have a 
protective role, some of these enzymes, such as CAPN1, generate C-terminally truncated 
fragments that seed the propagation of full-length α-syn following incomplete degradation 
of fibrillar α-syn (14, 38, 39). CAPN1 is increased in PD (40-42) and CAPN1 inhibitors are 
protective in an experimental mouse models of PD (41, 43). Most evidence for KLK6 
suggests that this enzyme has a protective function: i.e. proteolytic cleavage reduces α-syn 
α-syn aggregation and toxicity and facilitates clearance. The potential for CTSD cleavage 
fragments to promote aggregation remains to be determined. Further research is needed to 
define the role of these enzymes in the pathogenesis of MSA. 
Conclusion.  
We have shown that KLK6, CAPN1 and CTSD proteases are upregulated in MSA, particularly 
in regions with a high α-syn burden. The findings indicate that α-syn is unlikely to 
accumulate in MSA due to reduced activity of these enzymes. The upregulation of KLK6, 
CAPN1 and CTSD in MSA may be a compensatory response to elevated α-syn load. Further 
studies are required to determine the precise role of these enzymes in the pathogenesis of 
MSA.  
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Figure Legends: 
 Figure 1. Graphical representation of fold change in mRNA expression in MSA compared to 
control. Significantly greater KLK6 mRNA is detected in MSA frontal lobe compared to 
control (A). No significant difference in CTSD (B) or SNCA (C) mRNA expression is detected in 
MSA frontal lobe. No significant difference in detected in the mRNA expression of KLK6 (D), 
CTSD (E) or SNCA (F) in the cerebellar white matter of MSA cases compared to control. 
Figure 2. Graphical representation of levels of kallikrein-6 (KLK6) in control (C) and MSA (M) 
following western blot analysis. Densitometry analysis of immunoblots were performed in 
triplicate and normalised to β-actin for frontal lobe, putamen, caudate nucleus, pontine 
base, cerebellar white matter and occipital lobe. 
Figure 3. Graphical representation of levels of calpain-1 (CAPN1) in control (C) and MSA (M) 
following western blot analysis. Densitometry analysis of immunoblots were performed in 
triplicate and normalised to β-actin for frontal lobe, putamen, caudate nucleus, pontine 
base, cerebellar white matter and occipital lobe. 
Figure 4. Graphical representation of levels of cathepsin-D (CTSD) in control (C) and MSA (M) 
following western blot analysis. Densitometry analysis of immunoblots were performed in 
triplicate and normalised to β-actin for frontal lobe, putamen, caudate nucleus, pontine 
base, cerebellar white matter and occipital lobe. 
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Figure 5. Bar chart showing regional α-syn load in multiple system atrophy. α-syn load 
represents the percentage section area immunopositive for α-syn determined in putamen 
(PUT) caudate nucleus (caudate), pontine base (PNS), cerebellar white matter (CBM), 
occipital lobe (OCC) and frontal lobe (FCX)). Bars indicate the mean and SEM. **P < 0.01 
***P < 0.001 ****P < 0.0001.  
Figure 6. Bar charts showing differences in (A) KLK6 (B) CAPN1 and (C) CTSD in MSA across 
regions with different predilection for pathology. KLK6 protein levels, measured by sandwich 
ELISA and CAPN1 and CTSD enzyme activities using fluorogenic peptide substrate activity 
assays were measured in MSA (n=20) and controls (n=20) in putamen (PUT) caudate nucleus 
(caudate), pontine base (PNS), cerebellar white matter (CBM), occipital lobe (OCC) and 
frontal lobe (FCX)). Bars indicate the mean and SEM. *P < 0.05 ***P < 0.001 ****P < 0.0001.  
Figure 7. Regional association between (A) KLK6, (B) CAPN1, (C) CTSD and α-syn load in MSA 
and controls. The protein level or activity of each protease was plotted against α-syn load in 
putamen (PUT) caudate nucleus (caudate), pontine base (PNS), cerebellar white matter 
(CBM), occipital lobe (OCC) and frontal lobe (FCX)) in MSA cases. The solid circles and thin 
bars indicate the mean values and SEM for α-syn load (horizontal bars) and protease 
(vertical bars). The thick solid and dotted lines indicate the best-fit linear regression and 
95% confidence intervals. 
 
 
 
 
Page 23 of 31 Neuropathology and Applied Neurobiology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
  
 
 
Figure 2. Kallikrein-6 (KLK6) protein level in MSA  
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Patient Application used 
for 
Gender Age Post Mortem 
delay (h:m) 
Control 1  WB, IHC, A F 83 99:00 
Control 2  WB, IHC, A F 94 89.25 
Control 3  WB, IHC, A F 79 88:50 
Control 4  NS, CA, WB, IHC, A F 80 49:10 
Control 5  WB, IHC, A F 86 120:00 
Control 6  NS, CA, WB, IHC, A F 93 29:40 
Control 7  WB, IHC, A M 69 168.00 
Control 8  IHC, A F 87 51.45 
Control 9  NS, CA, IHC, A M 87 57.00 
Control 10  IHC, A F 92 63.5 
Control 11  IHC, A F 87 84.15 
Control 12  IHC, A F 91 53:25 
Control 13  IHC, A F 86 119:05 
Control 14  IHC, A M 88 97:30 
Control 15  IHC, A M 84 76.5 
Control 16  IHC, A M 95 89.2 
Control 17  NS, CA, IHC, A M 88 16:15 
Control 18  IHC, A M 83 60:00 
Control 19  CA, IHC, A  38 80.35 
Control 20  CA, IHC, A M 89 38:30 
MSA 1  WB, IHC, A F 68 36:35 
MSA 2  NS, CA, WB, IHC, A F 66 23:20 
MSA 3  WB, IHC, A F 62 118:35 
MSA 4  WB, IHC, A F 59 48:15 
MSA 5  WB, IHC, A M 69 43:15 
MSA 6  WB, IHC, A M 78 100:15 
MSA 7  WB, IHC, A F 71 80:00 
MSA 8  IHC, A F 70 83:15 
MSA 9  IHC, A F 70 64:45 
MSA 10  IHC, A M 72 89:49 
MSA 11  NS, CA, IHC, A F 60 35:30 
MSA 12  IHC, A M 66 107:20 
MSA 13  IHC, A M 51 56:10 
MSA 14  IHC, A F 52 72:30 
MSA 15  IHC, A F 68 107:00 
MSA 16  IHC, A M 54 25:35 
MSA 17  NS, CA, IHC, A M 63 20:40 
MSA 18  IHC, A F 55 29:02 
MSA 19  IHC, A M 63 26:55 
MSA 20  CA, IHC, A F 85 89:00 
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